摘要
目的:分析与探讨重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(益赛普)对强直性脊柱炎外周血细胞的影响.方法:选取我院2014-04/2015-04收治的强直性脊柱炎患者40例,对所有患者进行5周的益赛普治疗,其后评价临床治疗效果,并分析外周血细胞的变化规律.结果:40例患者经1周治疗后,强直性脊柱炎患者的白细胞总数同基线比较,下降显著,差异有统计学意义(P<0.05).进一步分析显示,重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗强直性脊柱炎,可以减少患者的血细胞计数.除此之外,该药物可以使患者的贫血现象得到明显改善,纠正异常血小板.结论:重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗强直性脊柱炎,可以改变患者的血液系统,因此在临床治疗中需要加强监测.
AIM： To analyze and discuss the influence of recombinant human tumor necrosis factor-Fc fusion protein（ etanercept）on peripheral blood cells in patients with ankylosing spondylitis.METHODS： A total of 40 patients with ankylosing spondylitis admitted to our hospital from April 2014 to 2015 were selected.All patients were treated by etanercept for five weeks. Curative effect was evaluated,and changes of peripheral blood cells were analyzed. RESULTS： After one weak treatment,white blood cells in patients with ankylosing spondylitis decreased significantly,compared with the baseline（ P〈0. 05）. Further analysis showed that recombinant human tumor necrosis factor-Fc fusion protein can reduce the patient＇s blood cell counts when used for treating patients ankylosing spondylitis. In addition,the drug can significantly improve the patient＇s anemia and regain the platelets. CONCLUSION： Recombinant human tumor necrosis factor-Fc fusion protein can improve the blood system of patients with ankylosing spondylitis,so the monitoring should be strengthened in clinics.
出处
《转化医学电子杂志》
2015年第10期38-39,共2页
E-Journal of Translational Medicine
